Apoptosis Gene Patterns Reveal Distinct AML Subgroups and Flag BIK as a Surprising Prognostic Marker

Acute myeloid leukemia has long been one of the most stubborn opponents in hematology, and much of that stubbornness traces back to a single biological trick: the cancer cells simply refuse to die. Chemotherapy and targeted drugs are designed to push malignant cells toward apoptosis, the tightly choreographed program of self-destruction that healthy cells undergo when they are damaged or no longer needed. In AML, that program is frequently jammed. Now a new study from researchers at the Medical University of Lodz in Poland suggests that the precise pattern in which apoptosis genes are switched on or off in leukemic cells may do far more than explain drug resistance — it may sort patients into fundamentally different disease groups and point to an unexpected marker of survival.

The research, published in Annals of Hematology, took a direct approach to a question that has lingered at the edge of AML biology for years. Rather than inferring apoptotic behavior from broad molecular signatures, the team prospectively measured messenger RNA expression of apoptosis-related genes in bone marrow mononuclear cells from 90 patients with newly diagnosed AML. Every sample came from patients at the start of their treatment journey, before therapy could reshape the transcriptional landscape of their leukemia. That design choice matters, because it allowed the investigators to ask whether the apoptotic wiring present at diagnosis could predict what happened next — how long patients lived, how they responded to treatment, and whether their disease returned.

When the researchers clustered patients according to their apoptosis gene expression profiles, two biologically distinct groups emerged, and the differences between them were striking. The first cluster carried a transcriptional pattern that, on its surface, looked almost reassuring: relatively higher expression of the classic anti-apoptotic gene BCL2, the very gene targeted by one of modern hematology’s most celebrated drugs. The second cluster told a more complicated story. These patients showed coordinated upregulation of a battery of pro-apoptotic genes, including BCL2L11 (better known as BIM), BBC3 (PUMA), BID, BAD, BIK, and BAX — genes whose protein products are supposed to push cells toward self-destruction. At the same time, the cells appeared to shift their survival strategy away from BCL2 and toward alternative anti-apoptotic regulators, with increased expression of MCL1 and BCL2L1, which encodes the survival protein BCL-xL.

That combination — more pro-death genes, but a survival apparatus rebuilt around different guardians — might seem paradoxical, and the clinical outcomes made the paradox impossible to ignore. Patients in the second cluster had significantly inferior overall survival. The researchers also observed reduced expression of CASP3 and CASP7, the executioner caspases that carry out the final, irreversible steps of apoptosis, in this high-risk group. Lower levels of these molecular executioners, the authors suggest, may mean that even when the death signal is triggered, the cell’s machinery for completing the process runs less efficiently. In other words, the leukemic cells of Cluster 2 patients appeared to be shouting the commands for self-destruction while simultaneously dismantling the equipment needed to obey them.

The timing of the study gives its findings particular weight. The treatment of AML has been transformed in recent years by venetoclax, a BCL2 inhibitor that, when combined with the hypomethylating agent azacitidine — a regimen known as VenAza — has become a backbone of therapy for older patients and those unfit for intensive chemotherapy. Venetoclax works by neutralizing BCL2, removing one of the main shields that leukemic cells use to resist apoptosis. If a patient’s leukemia depends heavily on BCL2, the drug should work well. If the cells have quietly reorganized their survival machinery around MCL1 or BCL-xL, the drug’s leverage diminishes. The Lodz team’s data fit that logic with unsettling precision: among patients treated with venetoclax plus azacitidine, those in Cluster 2 demonstrated significantly shorter event-free survival.

The biological features of Cluster 2 help explain why. The researchers noted that this subgroup displayed a monocytic immunophenotype, a characteristic that previous studies had already associated with reduced sensitivity to BCL2-targeted therapy. Monocytic AML cells tend to rely more on MCL1 and other alternative survival proteins than on BCL2 itself, making venetoclax a less effective key for that particular lock. Combined with the transcriptional evidence of increased MCL1 and BCL-xL expression and diminished executioner caspase activity, the picture that emerges is of a leukemia subtype that is not merely more aggressive, but differently engineered — one whose apoptotic architecture is fundamentally less vulnerable to the therapies now widely deployed against it.

Then comes the study’s most provocative single finding. When the researchers examined individual genes rather than cluster-level patterns, one stood out: BIK. Higher BIK mRNA expression was associated with poorer survival and with a lack of response to venetoclax-azacitidine therapy, and the association held up as an independent prognostic marker. The paradox here is sharp. BIK is a pro-apoptotic gene, a member of the BH3-only family whose role is to help tip cells into death. Higher expression of a death-promoting gene should, intuitively, be good news. Instead, in this cohort, it flagged the patients most likely to fare badly. The authors highlight this paradoxical association explicitly, and it serves as a reminder that gene expression in cancer rarely obeys simple intuition — context, coordination, and the surrounding molecular machinery determine whether a signal means surrender or defiance.

Why might high BIK expression accompany worse outcomes? The study’s cluster-level data suggest a plausible framework. In Cluster 2, BIK is upregulated alongside a host of other pro-apoptotic genes as part of a broader transcriptional state, one in which the cell simultaneously bolsters alternative survival pathways through MCL1 and BCL-xL and dampens the caspase machinery that would finalize apoptosis. In that setting, elevated BIK may be less a weapon than a distress signal — a marker of a cellular state in which death pathways are chronically activated yet chronically thwarted. Cells locked in such a standoff may be under persistent stress, and stress-adapted leukemic cells are often the most difficult to eradicate. BIK expression, on this reading, is not causing the poor prognosis but faithfully reporting it, which is precisely what a good biomarker should do.

The clinical implications ripple outward in several directions. First, the study demonstrates that apoptosis-related gene expression, measured at diagnosis, defines clinically distinct AML subgroups — a finding that could eventually inform how patients are risk-stratified beyond the current arsenal of cytogenetic and mutation-based markers. Second, the link between Cluster 2 biology and shortened event-free survival on venetoclax-azacitidine raises the possibility that expression profiling of apoptotic genes could help identify, upfront, which patients are unlikely to benefit from the regimen and might be better served by alternative or combination strategies, including agents targeting MCL1 that are currently in development. Third, the independent prognostic value of BIK offers a concrete, testable candidate for prospective validation in larger and more diverse cohorts.

Cautious interpretation remains essential. The cohort comprised 90 patients treated at a single center, and the findings, while internally coherent, will need replication before they reshape clinical practice. The authors themselves frame the results as demonstrating that dysregulation of apoptosis-related gene expression defines clinically distinct subgroups and may contribute to differences in prognosis and therapeutic response — a claim about mechanism and association rather than a prescription for immediate changes in care. Yet the conceptual shift the study proposes is substantial. AML has traditionally been classified by the mutations its cells carry; this work argues that how those cells manage life and death — the balance of pro- and anti-apoptotic forces, the choice of survival protein, the integrity of the caspase execution machinery — is itself a meaningful axis of disease biology. If subsequent studies confirm the pattern, the humble measurement of apoptosis gene mRNA could become a routine part of the diagnostic conversation, and the paradoxical signal from BIK could stand as a symbol of how much remains to be learned about why some leukemias die on command and others simply will not.

Subject of Research: Apoptosis-related gene expression profiling in acute myeloid leukemia and its association with patient clustering, prognosis, and response to venetoclax-based therapy

Article Title: Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker

Article References: Strzałka, K., Strzałka, P., Jarych, D., Wiśnik, A., Mikulski, D., Kościelny, K., Czemerska, M., Zawlik, I., Wierzbowska, A., & Pluta, A. (2026). Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker. Annals of Hematology. https://doi.org/10.1007/s00277-026-07268-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07268-7

Keywords: acute myeloid leukemia, apoptosis, gene expression profiling, BIK, venetoclax, azacitidine, BCL2, MCL1, prognostic marker, drug resistance, caspases, hematology